drugset / Trial / NCT05050760
DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
NaSingle-groupOpen-labelHealth-services research
Summary
To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC
Timeline
- Start
- 2021-09-01
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 40 mg | — |
| Subject | S-1 | Small molecule | 50 mg | — |